Muscular dystrophy drugs face new FDA questions
from The Wall Street Journal
Hopes are dimming that the drug industry will be able to quickly deliver a treatment for one of the most keenly researched diseases of recent years — an inherited muscle-wasting disorder called Duchenne muscular dystrophy. Advances in understanding the disease sparked a research and development boom in recent years, and fueled excitement that boosted some small companies’ stock prices.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063